Tag Archive for: NIAID
Biden wishes to spend billions more on COVID-19 efforts at home and abroad. US federal funding agencies haven’t discussed specific funding opportunities based on the administration’s proposals, but it is likely there will be more funding available to biotech R&D on anti-virals, vaccines, diagnostics, etc.
Dr. Natalia Kruchinin discusses non-dilutive funding opportunities at NIAID and NIH.
The National Institute of Allergy & Infectious Diseases (NIAID) has just published a Broad Agency Announcement (BAA). This BAA contains four distinct Research Areas: Vaccines, Therapeutics, and In-Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections and Emerging Infectious Diseases, and Antivirals for Specific RNA Viral Families of Pandemic Potential.
FreeMind can help you apply for these funds or for other non-dilutive grants and contracts. FreeMind will host a webinar about the BAA on February 7, at 1:00 PM EST.
Purpose: To solicit research applications for milestone-driven projects focused on preclinical development of lead candidate countermeasures (therapeutics, vaccines and related technologies, or diagnostics) against select NIAID Emerging Infectious Diseases/Pathogens.
Application Due Date: October 3, 2016
Budget: Direct costs of up to $750,000 per year may be requested. Applicants may also request up to an additional $300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling $1,050,000 direct costs.
Total Award: ~4,000,000 over 5 years
To discuss this opportunity or to learn about other non-dilutive funding that may be relevant to your organization, send us a note and we’ll get in touch with you directly!
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109